Medication-overuse headache in patients with cluster headache
Abstract
Objective: Medication-overuse headache (MOH) in cluster headache (CH) patients is incompletely described, perhaps because of the relatively low prevalence of CH.
Methods: The authors describe a retrospective series of 17 patients (13 men, 4 women) with CH who developed MOH in association with overuse of a wide range of monotherapies or varying combinations of simple analgesics (n = 9), caffeine (n = 1), opioids (n = 10), ergotamine (n = 3), and triptans (n = 14). The series includes both episodic (n = 7) and chronic (n = 10) CH patients.
Results: A specific triptan-overuse headache diagnosis was made in 3 patients, an opioid-overuse headache diagnosis was made in 1 patient, and an ergotamine-overuse headache diagnosis was made in 1 patient. In approximately half of the patients (n = 8), the MOH phenotype was a bilateral, dull, and featureless daily headache. In the other 9 patients, the MOH was characterized by at least one associated feature, most commonly nausea (n = 6), exacerbation with head movement (n = 5), or throbbing character of the pain (n = 5). The common denominator in 15 patients was a personal or family history, or both, of migraine. The 2 other patients gave a family history of unspecified headaches. Medication withdrawal was attempted and successful in 13 patients.
Conclusions: Medication-overuse headache is a previously underrecognized and treatable problem associated with cluster headache (CH). CH patients should be carefully monitored, especially those with a personal or family history of migraine.
Get full access to this article
View all available purchase options and get full access to this article.
Supplementary Material
References
1.
Mathew NT. Transformed or evolutional migraine. Headache 1987;27:305–306.
2.
Fritsche G, Diener HC. Medication overuse headaches: what is new? Expert Opin Drug Saf 2002;1:331–338.
3.
Young WB, Silberstein SD. Hemicrania continua and symptomatic mediation overuse. Headache 1993;33:485–487.
4.
Evans RW. New daily persistent headache. Curr Pain Headache Rep 2003;7:303–307.
5.
Silberstein SD, Lipton RB, Goadsby PJ. Headache in clinical practice. London: Martin Dunitz, 2002
6.
Hering-Hanit R. Alteration in nature of cluster headache during subcutaneous administration of sumatriptan. Headache 2000;40:41–44.
7.
Hardebo JE. Subcutaneous sumatriptan in cluster headache: a time study in the effect of pain and autonomic symptoms. Headache 1993;33:18–21.
8.
Rossi P, Lorenzo GD, Formisano R, Buzzi MG. Subcutaneous sumatriptan induces changes in frequency pattern in cluster headache patients. Headache 2004;44:713–718.
9.
Dousset V, Chrystome V, Ruiz B, et al. Does repeated subcutaneous administration of sumatriptan produce an unfavorable evolution in cluster headache? J Headache Pain 2004;5:110–114.
10.
Turhal NS. Sumatriptan overdose in episodic cluster headache: a case report of overuse without event. Cephalalgia 2001;21:700.
11.
Centonze V, Bassi A, Causarano V, et al. Sumatriptan overuse in episodic cluster headache: lack of adverse events, rebound syndromes, drug dependence and tachyphylaxis. Funct Neurol 2000;15:167–170.
12.
Gobel H, Lindner A, Heinze A, Ribbat M, Deuschl G. Acute therapy for cluster headache with sumatriptan: findings of a one year long-term study. Neurology 1998;51:908–911.
13.
Lenaerts ME. Cluster headache and cluster variants. Curr Treat Options Neurol 2003;5:455–466.
14.
Evers S, Bauer B, Suhr B. Ergotamine-induced headache associated with cluster headache. Neurology 1996;46:291–.
15.
Sjaastad O, Bakketeig LS. Cluster headache prevalence: Vaga study of headache epidemiology. Cephalalgia 2003;23:528–533.
16.
Katsarava Z, Schneeweiss S, Kurth T, et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 2004;62:788–790.
17.
Paemeleire K, Bahra A, Evers S, Matharu MS, Goadsby PJ. Medication-overuse headache in cluster headache patients. Cephalalgia 2004;24:1101.
18.
Headache Classification Committee of The International Headache Society. The International Classification of Headache Disorders (second edition). Cephalalgia 2004;24:1–160.
19.
Silberstein SD, Niknam R, Rozen TD, Young WB. Cluster headache with aura. Neurology 2000;54:219–221.
20.
Bahra A, May A, Goadsby PJ. Cluster headache: a prospective clinical study in 230 patients with diagnostic implications. Neurology 2002;58:354–361.
21.
Bahra A, Walsh M, Menon S, Goadsby PJ. Does chronic daily headache arise de novo in association with regular analgesic use? Headache 2003;43:179–190.
22.
Nappi G, Micieli G, Cavallini A, et al. Accompanying symptoms of cluster attacks: their relevance to the diagnostic criteria. Cephalalgia 1992;12:165–168.
23.
Irimia P, Cittadini E, Paemeleire K, et al. Unilateral phonophobia and photophobia: a helpful symptom for the diagnosis of trigeminal autonomic cephalalgias (TACs) and hemicrania continua (HC). Cephalalgia 2005;25:856.
24.
Limmroth V, Katsarava Z, Fritsche G, Przywara S, Diener H-C. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002;59:1011-1014.
25.
Bennett WM, DeBroe ME. Analgesic nephropathy: a preventable renal disease. N Engl J Med 1989;320:1269–1271.
26.
Roth SH. From peptic ulcer disease to NSAID gastropathy: an evolving nosology. Drugs Aging 1995;6:358–367.
27.
Meyler WJ. Side effects of ergotamine. Cephalalgia 1996;16:5–10.
28.
Levy M, Matharu MS, Meeran K, Powell M, Goadsby PJ. The clinical characteristics of headache in patients with pituitary tumours. Brain 2005;128:1921–1930.
29.
Ekbom K. Migraine in patients with cluster headache. Headache 1974;14:69–72.
30.
Bickerstaff ER. The periodic migrainous neuralgia of Wilfred Harris. Lancet 1959;I:1069–1071.
31.
Steiner TJ, Scher AI, Stewart WF, et al. The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia 2003;23:519–527.
32.
Pascual J, Colas R, Castillo J. Epidemiology of chronic daily headache. Curr Pain Headache Rep 2001;5:529–536.
33.
Scher A, Stewart WF, Liberman J, Lipton RB. Prevalence of frequent headache in a population sample. Headache 1998;38:497–506.
34.
Lipton RB, Dodick D, Sadovsky R, et al. A self-administered screener for migraine in primary care: The ID Migraine(TM) validation study. Neurology 2003;61:375–382.
35.
Lipton RB, Bigal ME, Dowson A, Stewart WF. Familial risk of migraine: variation by proband age of onset, and headache severity. Neurology 2005;64:A134.
36.
Zwart J-A, Dyb G, Hagen K, Svebak S, Holmen J. Analgesic use: a predictor of chronic pain and medication overuse headache. Neurology 2003;61:160–164.
37.
Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 2003;106:81–89.
38.
Wang S-J, Fuh J-L, Lu S-R, et al. Chronic daily headache in Chinese elderly: prevalence, risk factors and biannual follow-up. Neurology 2000;54:314–319.
39.
Matharu MS, Boes CJ, Goadsby PJ. Management of trigeminal autonomic cephalalgias and hemicrania continua. Drugs 2003;63:1637–1677.
40.
Ekbom K. The Sumatriptan Cluster Headache Study Group. Treatment of acute cluster headache with sumatriptan. N Engl J Med 1991;325:322–326.
41.
D'Amico D, Centonze V, Grazzi L, et al. Coexistence of migraine and cluster headache: report of 10 cases and possible pathogenetic implications. Headache 1997;37:21–25.
Information & Authors
Information
Published In
Copyright
© 2006.
Publication History
Published online: July 10, 2006
Published in print: July 11, 2006
Authors
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Healthcare disparities encountered by patients with headache disorders and potential mitigation strategies, Migraine Management, (569-582), (2024).https://doi.org/10.1016/B978-0-12-823357-3.00016-1
- Cluster headache: state of the art in treatment, Frontiers in Pain Research, 4, (2023).https://doi.org/10.3389/fpain.2023.1265540
- Medication-overuse headache—a review of different treatment strategies, Frontiers in Pain Research, 4, (2023).https://doi.org/10.3389/fpain.2023.1103497
- Management of cluster headache: Treatments and their mechanisms, Cephalalgia, 43, 8, (2023).https://doi.org/10.1177/03331024231196808
- Prevalence, natural history and dynamic nature of chronic headache and medication overuse headache in Italy: The SPARTACUS study, Cephalalgia, 43, 4, (033310242311576), (2023).https://doi.org/10.1177/03331024231157677
- European Academy of Neurology guidelines on the treatment of cluster headache, European Journal of Neurology, 30, 10, (2955-2979), (2023).https://doi.org/10.1111/ene.15956
- Trigeminal Autonomic Cephalalgias and Neuralgias in Children and Adolescents: a Narrative Review, Current Neurology and Neuroscience Reports, 23, 9, (539-549), (2023).https://doi.org/10.1007/s11910-023-01288-w
- BLOQUEIO NERVOSO PERIFÉRICO COMO TRATAMENTO CIRÚRGICO PARA DOR DE CABEÇA DE USO EXCESSIVO DE MEDICAMENTOS: DOIS RELATÓRIOS DE CASO, RECISATEC - REVISTA CIENTÍFICA SAÚDE E TECNOLOGIA - ISSN 2763-8405, 2, 1, (e2173), (2022).https://doi.org/10.53612/recisatec.v2i1.73
- Evaluation and treatment of medication-overuse headache: Russian experts’ guidelines, Neurology, Neuropsychiatry, Psychosomatics, 14, 1, (4-13), (2022).https://doi.org/10.14412/2074-2711-2022-1-4-13
- Epidemiology of diagnosed cluster headache in Norway, Cephalalgia Reports, 5, (251581632210755), (2022).https://doi.org/10.1177/25158163221075569
- See more
Loading...
View Options
Get Access
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.